🔎 Trials Near Me

Beranda › Mieloma Multipel › Minnesota

Uji klinis Mieloma Multipel di Minnesota

30 studi untuk Mieloma Multipel mencari peserta di lokasi di Minnesota.

Kota di Minnesota

Teks studi resmi (Bahasa Inggris)

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

  • Mayo Clinic Health System in Albert Lea, Albert Lea
  • Mayo Clinic Health System-Mankato, Mankato
  • Mayo Clinic in Rochester, Rochester
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06630104

SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders

  • Mayo Clinic in Rochester, Rochester
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07850284

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  • University Of Minnesota Medical Center, Minneapolis
  • Mayo Clinic, Rochester
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07518186

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic Rochester, Rochester
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07258511

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  • Mayo Clinic, Rochester
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07393282

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

  • Mayo Clinic Rochester, Rochester
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05201781

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

  • Minnesota Oncology - Minneapolis Clinic /ID# 278720, Minneapolis
  • Mayo Clinic Hospital Rochester /ID# 277886, Rochester
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07095452

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic in Rochester, Rochester
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06465316

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic in Rochester, Minnesota, Rochester
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06297226

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic Rochester, Rochester
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT06375044

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic in Rochester, Rochester
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06940297

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • Minnesota Oncology - Burnsville, Burnsville
  • Cambridge Medical Center, Cambridge
  • Minnesota Oncology Hematology PA-Chaska, Chaska
  • dan 24 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT04566328

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

  • Mayo Clinic - Transplant Center - Rochester, Rochester
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT05651932

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  • Research Site, Minneapolis
  • Research Site, Rochester
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT05850234

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  • Mayo Clinic - Minnesota, Rochester
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07284758

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

  • Mayo Clinic in Rochester, Minnesota, Rochester
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jul 2026 · NCT06121843

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Mayo Clinic - Rochester /ID# 251164, Rochester
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT05650632

Integrated Cancer Repository for Cancer Research

  • Riverwood Healthcare Center, Aitkin
  • Essentia Health-St. Joseph's Medical Center, Brainerd
  • Essentia Health - Duluth Clinic, Duluth
  • dan 2 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

  • Mayo Clinic in Rochester, Rochester
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Jun 2026 · NCT06785415

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

  • Masonic Cancer Center at University of Minnesota, Minneapolis
Menerima pesertaFase 2
Hingga usia 60 · Semua jenis kelamin · Diperbarui 25 Jun 2026 · NCT03314974

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  • Riverwood Healthcare Center, Aitkin
  • Essentia Health - Baxter Clinic, Baxter
  • Sanford Joe Lueken Cancer Center, Bemidji
  • dan 40 lainnya
Menerima pesertaFase 3
Semua usia · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT05561387

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

  • University of Minnesota - Masonic Cancer Center, Minneapolis
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Jun 2026 · NCT03858205

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

  • Minnesota Oncology Hematology, Minneapolis
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Apr 2026 · NCT05972135

Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma

  • Mayo Clinic in Rochester, Rochester
Menerima peserta
Usia 65 ke atas · Semua jenis kelamin · Diperbarui 13 Apr 2026 · NCT06145581

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Allina Health Cancer Institute, Minneapolis
  • Mayo Clinic, Rochester
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT05366881

Family Study of Lymphoproliferative Disorders

  • Mayo Clinic, Rochester
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 14 Okt 2025 · NCT00626496

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

  • University of Minnesota, Minneapolis
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2025 · NCT06119685

Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma

  • Center for International Blood and Marrow Transplant Research, Minneapolis
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 30 Agu 2023 · NCT03127761

Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.